Ваша корзина
пуста
Перейти в корзину

Риски общесоматических осложнений у пациентов, принимающих синтетические катиноны. Обзор литературы

Авторы:
Анисимова Е.Н., Лабзенкова М.А., Маркосян С.Г., Рыжков Д.Д., Семёнов А.Д.
Научно-практический журнал Институт Стоматологии №2(95), июнь 2022
стр. 80-81
Стоимость:
Бесплатно
(в формате PDF)
Аннотация
На основании анализа литературы, осуществленного на базах: PubMed, Medline, CSEN, BioMedNed, PMC, Academia, определены особенности фармакокинетики и фармакодинамики синтетических катинонов, используемых пациентами, с целью прогноза развития риска общесоматических осложнений в условиях амбулаторного стоматологического приема.
Аннотация (англ)
Based on the analysis of the literature carried out on the basis of: PubMed, Medline, CSEN, BioMedNed, PMC, Academia, the features of the pharmacokinetics and pharmacodynamics of synthetic cathinones used by patients were determined in order to predict the development of the risk of general somatic complications in an outpatient dental appointment.
Ключевые Слова
наркотическая зависимость, синтетические катиноны, риск развития общесоматических осложнений.
Ключевые Слова (англ)
drug addiction, synthetic cathinones, risk of general somatic complications.
Список литературы
1. Анцыборов А.В., Асадуллин А.Р. Психоактивные эффекты и токсические реакции, связанные с употреблением мефедрона и метилона (обзор литературы) // Интерактивная наука. - 2017. - № 9 (19).
2. Анцыборов А.В., Мрыхин В.В. Синтетические катиноны “Соли для ванн”: механизм действия, токсикологические аспекты, клиника, формирование зависимости // Интерактивная наука. - 2017. - № 15.
3. Международная классификация болезней 11-го пересмотра (МКБ-11). https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f1605818663).
4. Мрыхин В.В., Анцыборов А.В. Психиатрические аспекты употребления дизайнерских наркотиков и новых психоактивных веществ // Интерактивная наука. - 2017. - № 12.
5. Baumann M.H., Partilla J.S., Lehner K.R., Thorndike E.B., Hoffman A.F., Holy M., Rothman R.B., Goldberg S.R., Lupica C.R., Sitte H.H., Brandt S.D., Tella S.R., Cozzi N.V., Schindler C.W. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology. 2013;38:552-562.
6. Brunt T.M., Poortman A., Niesink R.J., van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol. 2011 Nov;25(11):1543-7. doi: 10.1177/0269881110378370. Epub 2010 Sep 8. PMID: 20826554.
7. Boozer C.N., Daly P.A., Home P., Solomon J.L., Blanchard D., Nasser J.A., Strauss R. and Meredith T. “Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial” Int J Obes May 2002, Volume 26, Number 5, Pages 593-604.
8. Henry J.A., Fallon J.K., Kicman A.T., Hutt A.J., Cowan D.A., Forsling M. Low-dose MDMA (“ecstasy”) induces vasopressin secretion. Lancet 1998; 351(9118): 1784, 143.
9. James D., Adams R.D., Spears R. et al (2010) Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service.
10. Khreit, O.I., Grant M.H., Zhang T., Henderson C., Watson D.G.
and Sutcliffe O.B. Elucidation of the Phase I and Phase II metabolic pathways of (±)-4’-methylmethcathinone (4-MMC) and (±)-4’-(trifl uoromethyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MS². J Pharm Biomed Anal, 2013. 72: p. 177-85.
11. Larchenko А.V. et al. “Synthetic cathinones and cannabinoids are new psychoactive substances (review).” Sovremennye tehnologii v medicine (2017); 9(1): 185-197.
12. Liechti M. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly. 2015;145:w14043.
13. Meyer M.R., Wilhelm J., Peters F.T., Maurer H.H. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem. 2010;397:1225-1233.
14. Prosser, J.M., Nelson, L.S. The Toxicology of Bath Salts: A Review of Synthetic Cathinones. J. Med. Toxicol. 8, 33-42 (2012).
15. Schifano F. Novel psychoactive substances (NPS): clinical and pharmacological issues //Drugs and Alcohol Today. - 2015. - Т. 15. - №. 1. - С. 21-27.
16. Simmler L.D., Buser T.A., Donzelli M., Schramm Y., Dieu L.H., Huwyler J., Chaboz S., Hoener M.C., Liechti M.E. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168:458-470.
17. Strano-Rossi S., Cadwallader A.B., de la Torre X., Botrè F. (2010). Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 24(18):2706-2714.
18. Stuart H.R., Ian D.P., Mark W.J., Richard P.H. // Davidcon’s Principles and Practice of Medicine. - 2015: 165.
19. Zaitsu K., Katagi M., Kamata H.T. et al (2009). Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int 188(1-3):131-139.

REFERENCES:
1. Ancyborov A.V., Asadullin A.R. Psihoaktivnye effekty i toksicheskie reakcii, svyazannye s upotrebleniem mefedrona i metilona (obzor literatury) //Interaktivnaya nauka. - 2017. - № 9 (19).
2. Ancyborov A.V., Mryhin V.V. Sinteticheskie katinony “Soli dlya vann”: mekhanizm dejstviya, toksikologicheskie aspekty, klinika, formirovanie zavisimosti //Interaktivnaya nauka. - 2017. - № 15.
3. Mezhdunarodnaya klassifikaciya boleznej 11-go peresmotra (MKB-11). https://icd.who.int/browse11/l-m/en#/http%3a%2f%2fid.who.int%2ficd%2fentity%2f1605818663).
4. Mryhin V.V., Ancyborov A.V. Psihiatricheskie aspekty upotrebleniya dizajnerskih narkotikov i novyh psihoaktivnyh veshchestv //Interaktivnaya nauka. - 2017. - № 12.
5. Baumann M.H., Partilla J.S., Lehner K.R., Thorndike E.B., Hoffman A.F., Holy M., Rothman R.B., Goldberg S.R., Lupica C.R., Sitte H.H., Brandt S.D., Tella S.R., Cozzi N.V., Schindler C.W. Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive ‘bath salts’ products. Neuropsychopharmacology. 2013;38:552-562.
6. Brunt T.M., Poortman A., Niesink R.J., van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol. 2011 Nov;25(11):1543-7. doi: 10.1177/0269881110378370. Epub 2010 Sep 8. PMID: 20826554.
7. Boozer C.N., Daly P.A., Home P., Solomon J.L., Blanchard D., Nasser J.A., Strauss R. and Meredith T. “Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial” Int J Obes May 2002, Volume 26, Number 5, Pages 593-604.
8. Henry J.A., Fallon J.K., Kicman A.T., Hutt A.J., Cowan D.A., Forsling M.
Low-dose MDMA (“ecstasy”) induces vasopressin secretion. Lancet 1998; 351(9118): 1784, 143.
9. James D., Adams R.D., Spears R. et al (2010) Clinical characteristics of mephedrone toxicity reported to the UK National Poisons Information Service.
10. Khreit, O.I., Grant M.H., Zhang T., Henderson C., Watson D.G. and Sutcliffe O.B. Elucidation of the Phase I and Phase II metabolic pathways of (±)-4’-methylmethcathinone (4-MMC) and (±)-4’-(trifl uoromethyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MS². J Pharm Biomed Anal, 2013. 72: p. 177-85.
11. Larchenko А.V. et al. “Synthetic cathinones and cannabinoids are new psychoactive substances (review).” Sovremennye tehnologii v medicine (2017); 9(1): 185-197.
12. Liechti M. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly. 2015;145:w14043.
13. Meyer M.R., Wilhelm J., Peters F.T., Maurer H.H. Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem. 2010;397:1225-1233.
14. Prosser, J.M., Nelson, L.S. The Toxicology of Bath Salts: A Review of Synthetic Cathinones. J. Med. Toxicol. 8, 33-42 (2012).
15. Schifano F. Novel psychoactive substances (NPS): clinical and pharmacological issues //Drugs and Alcohol Today. - 2015. - Т. 15. - №. 1. - С. 21-27.
16. Simmler L.D., Buser T.A., Donzelli M., Schramm Y., Dieu L.H., Huwyler J., Chaboz S., Hoener M.C., Liechti M.E. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168:458-470.
17. Strano-Rossi S., Cadwallader A.B., de la Torre X., Botrè F. (2010). Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 24(18):2706-2714.
18. Stuart H.R., Ian D.P., Mark W.J., Richard P.H. // Davidcon’s Principles and Practice of Medicine. - 2015: 165.
19. Zaitsu K., Katagi M., Kamata H.T. et al (2009). Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine. Forensic Sci Int 188(1-3):131-139.

Другие статьи из раздела «Обзор литературы в стоматологии»

  • Комментарии
Загрузка комментариев...